Analysis of the genome to personalize therapy for melanoma

Oncogene

Volumn 29, Issue 41, 2010, Pages 5545-5555

  Davies, M A ^a   Samuels, Y ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

BRAF; C KIT; ERBB4; GN Q; melanoma; NRAS

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALPHA2B INTERFERON; AZ 628; B RAF KINASE; BRAF INHIBITOR; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; G PROTEIN COUPLED RECEPTOR; IMATINIB; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4032; PROTEIN INHIBITOR; RAS PROTEIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; GENE MUTATION; GENE TARGETING; GENOME ANALYSIS; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 77957982878     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.323     Document Type: Review

References (118)

1. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R et al. (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18: 29-35.
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
3. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP et al. (2007). L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257-264.
4. Ashida A, Takata M, Murata H, Kido K, Saida T. (2009). Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862-868.
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1): S11-S14.
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116.
7. Baguley BC. (2010). Multidrug resistance in cancer. Methods Mol Biol 596: 1-14.
8. Baker M. (2008). Melanoma in mice casts doubt on scarcity of cancer stem cells. Nature 456: 553.
9. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. (1998). Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170-2175.
10. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14: 6821-6828.
11. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P. (2000). Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 114: 277-280.
12. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hemato-poietic cell. Nat Med 3: 730-737.
13. Bos JL. (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
14. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ et al. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297.
15. Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, van der Eb AJ et al. (1985). Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315: 726-730.
16. Brazil DP, Park J, Hemmings BA. (2002). PKB binding proteins. Getting in on the Akt. Cell 111: 293-303.
17. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000.
18. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
19. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
20. Chudnovsky Y, Khavari PA, Adams AE. (2005). Melanoma genetics and the development of rational therapeutics. J Clin Invest 115: 813-824.
21. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J et al. (2003). Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 2876-2878.
22. Courtney KD, Corcoran RB, Engelman JA. (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
23. Cruz III F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A et al. (2003). Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63: 5761-5766.
24. Curtin JA, Busam K, Pinkel D, Bastian BC. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346.
25. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
26. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr. WE et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552.
27. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
28. Davies M, Hennessy B, Mills GB. (2006). Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7: 2243-2261.
29. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN et al. (2009). Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15: 7538-7546.
30. Downward J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
31. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D et al. (2010). Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70: 2264-2273.
32. Eaves CJ. (2008). Cancer stem cells: here, there, everywhere? Nature 456: 581-582.
33. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006). Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. Br J Cancer 95: 581-586.
34. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106: 20411-20416.
35. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
36. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T et al. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23: 569-575.
37. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E et al. (2010). Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23: 14-26.
38. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M et al. (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836-4842.
39. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. (1987). Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303.
40. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126: 154-160.
41. Gray-Schopfer V, Wellbrock C, Marais R. (2007). Melanoma biology and new targeted therapy. Nature 445: 851-857.
42. Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660-3663.
43. WT melanoma cells. Pigment Cell Melanoma Res 23: 190-200.
44. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. (2006). Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12: 2301s-2307s.
45. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al. (2010). Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23: 210-215.
46. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
47. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823-2830.
48. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B et al. (2008). Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer 112: 982-994.
49. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
50. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202.
51. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580. (Pubitemid 28067289)
52. Hocker T, Tsao H. (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28: 578-588.
53. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26: 2046-2051.
54. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al. (1996). Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339-2347.
55. Inman JL, Kute T, White W, Pettenati M, Levine EA. (2003). Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 84: 82-88.
56. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W et al. (2009a). Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474.
57. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y et al. (2009b). Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 4: e5717.
58. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
59. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14: 7726-7732.
60. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298.
61. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
62. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99: 734-740.
63. Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17.
64. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. (2004). A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670-1677.
65. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. (2007). Post-translational modifications and regulation of the RAS super-family of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555.
66. Lassam N, Bickford S. (1992). Loss of c-kit expression in cultured melanoma cells. Oncogene 7: 51-56.
67. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
68. Maat W, Kilic E, Luyten GPM, de Klein A, Jager MJ, Gruis NA et al. (2008). Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49: 23-27.
69. Maehama T, Dixon JE. (1998). The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phospha-tidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
70. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J et al. (2005). CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104: 1045-1048.
71. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescencelike cell cycle arrest of human naevi. Nature 436: 720-724.
72. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861.
73. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95: 13513-13518.
74. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C et al. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461: 272-276.
75. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
76. Omholt K, Krockel D, Ringborg U, Hansson J. (2006). Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 16: 197-200.
77. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49: 5230-5234.
78. Padua RA, Barrass NC, Currie GA. (1985). Activation of N-ras in a human melanoma cell line. Mol Cell Biol 5: 582-585.
79. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249-254.
80. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. (2001). Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19: 3477-3482.
81. 0-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429.
82. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196.
83. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
84. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR et al. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127-1132.
85. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
86. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. (2008). Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5: 737-740.
87. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L et al. (2003). Lack of BRAF mutations in uveal melanoma. Cancer Res 63: 5712-5715.
88. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al. (2008). C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452: 27-32.
89. Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW et al. (1998). In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA 95: 9418-9423.
90. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. (1987). Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935.
91. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
92. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
93. Schwartz RN, Stover L, Dutcher J. (2002). Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16: 11-20.
94. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
95. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R et al. (2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28: 85-94.
96. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64: 7002-7010.
97. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
98. Strumberg D. (2005). Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41: 773-784.
99. Suarez HG, Du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C et al. (1988). Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2: 403-406.
100. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039.
101. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K et al. (2008). Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610.
102. Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP et al. (1995). Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83: 93-104.
103. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al. (2009). Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22: 1446-1456.
104. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041-3046.
105. Tsao H, Atkins MB, Sober AJ. (2004a). Management of cutaneous melanoma. N Engl J Med 351: 998-1012.
106. Tsao H, Goel V, Wu H, Yang G, Haluska FG. (2004b). Genetic interaction between NRAS and BRAF mutations and PTEN// MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341.
107. Tsao H, Zhang X, Benoit E, Haluska FG. (1998). Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397-3402.
108. Turner EH, Lee C, Ng SB, Nickerson DA, Shendure J. (2009). Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods 6: 315-316.
109. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92: 1398-1405.
110. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599-602.
111. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
112. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
113. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al. (2009). Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8: 2079-2085.
114. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al. (2006). Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106: 2005-2011.
115. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160-1162.
116. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L et al. (1997). Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272: 10232-10239.
117. Zhao L, Vogt PK. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496.
118. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. (2000). Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157: 1123-1128.